PDF(Pubmed)
Abstract：
UNASSIGNED: In December 2019, a novel epidemic of coronavirus pneumonia (COVID-19) was reported，and population-based studies had shown that cancer was a risk factor for death from COVID-19 infection. However, the molecular mechanism between COVID-19 and cancer remains indistinct. In this paper, we analyzed the nucleic acid sensor (DDX58) of SARS-CoV-2 virus, which is a significant gene related to virus infection. For purpose of clarifying the characteristics of DDX58 expression in malignant tumors, this study began to systematically analyze the DDX58 expression profile in the entire cancer type spectrum.
UNASSIGNED: Using TCGA pan-cancer database and related data resources, we analyzed the expression, survival analysis, methylation expression, mutation status, microsatellite instability (MSI), immune related microenvironment, gene related network, function and drug sensitivity of DDX58.
UNASSIGNED: The expression level of DDX58 mRNA in most cancers was higher than the expression level in normal tissues. Through TIMER algorithm mining, we found that DDX58 expression was closely related to various levels of immune infiltration in pan-cancer. The promoter methylation level of DDX58 was significantly increased in multiple cancers. In addition, abnormal expression of DDX58 was related to MSI and TMB in multiple cancers, and the most common type of genomic mutation was \"mutation.\" In the protein-protein interaction (PPI) network, we found that type I interferon, phagocytosis, ubiquitinase, and tumor pathways were significantly enriched. Finally, according to the expression of DDX58 indicated potential sensitive drugs such as Cediranib, VE-821, Itraconazole, JNJ-42756493, IWR-1, and Linsitinib.
UNASSIGNED: In conclusion, we had gained new insights into how DDX58 might contribute to tumor development, and DDX58 could be used as an immune-related biomarker and as a potential immunotherapeutic target for COVID-19 infected cancer patients.
UNASSIGNED: Using TCGA pan-cancer database and related data resources, we analyzed the expression, survival analysis, methylation expression, mutation status, microsatellite instability (MSI), immune related microenvironment, gene related network, function and drug sensitivity of DDX58.
UNASSIGNED: The expression level of DDX58 mRNA in most cancers was higher than the expression level in normal tissues. Through TIMER algorithm mining, we found that DDX58 expression was closely related to various levels of immune infiltration in pan-cancer. The promoter methylation level of DDX58 was significantly increased in multiple cancers. In addition, abnormal expression of DDX58 was related to MSI and TMB in multiple cancers, and the most common type of genomic mutation was \"mutation.\" In the protein-protein interaction (PPI) network, we found that type I interferon, phagocytosis, ubiquitinase, and tumor pathways were significantly enriched. Finally, according to the expression of DDX58 indicated potential sensitive drugs such as Cediranib, VE-821, Itraconazole, JNJ-42756493, IWR-1, and Linsitinib.
UNASSIGNED: In conclusion, we had gained new insights into how DDX58 might contribute to tumor development, and DDX58 could be used as an immune-related biomarker and as a potential immunotherapeutic target for COVID-19 infected cancer patients.
摘要：
未经评估：2019年12月，报告了新型冠状病毒肺炎（COVID-19）的流行，基于人群的研究表明癌症是COVID-19感染死亡的危险因素。然而,COVID-19与癌症之间的分子机制仍不清楚。在本文中,我们分析了SARS-CoV-2病毒的核酸传感器（DDX58），这是一个与病毒感染有关的重要基因。为了阐明DDX58在恶性肿瘤中的表达特征，本研究开始系统分析DDX58在整个癌症类型谱中的表达谱。
UNASSIGNED：使用TCGA泛癌症数据库和相关数据资源，我们分析了表达式，生存分析,甲基化表达，突变状态,微卫星不稳定性（MSI），免疫相关微环境，基因相关网络，DDX58的功能和药物敏感性。
UNASSIGNED：大多数癌症中DDX58mRNA的表达水平高于正常组织中的表达水平。通过TIMER算法挖掘,我们发现DDX58的表达与泛癌症中不同程度的免疫浸润密切相关。DDX58的启动子甲基化水平在多种癌症中显著升高。此外,DDX58的异常表达与多种癌症中的MSI和TMB有关，最常见的基因组突变类型是“突变”。“在蛋白质-蛋白质相互作用(PPI)网络中，我们发现了I型干扰素,吞噬作用,泛素酶，肿瘤通路显著丰富。最后,根据DDX58的表达表明潜在的敏感药物，如西迪拉尼布，VE-821,伊曲康唑,JNJ-42756493、IWR-1和Linsitinib。
未经批准：总而言之，我们获得了DDX58如何促进肿瘤发展的新见解，和DDX58可用作免疫相关的生物标志物，并作为COVID-19感染癌症患者的潜在免疫治疗靶点。
UNASSIGNED：使用TCGA泛癌症数据库和相关数据资源，我们分析了表达式，生存分析,甲基化表达，突变状态,微卫星不稳定性（MSI），免疫相关微环境，基因相关网络，DDX58的功能和药物敏感性。
UNASSIGNED：大多数癌症中DDX58mRNA的表达水平高于正常组织中的表达水平。通过TIMER算法挖掘,我们发现DDX58的表达与泛癌症中不同程度的免疫浸润密切相关。DDX58的启动子甲基化水平在多种癌症中显著升高。此外,DDX58的异常表达与多种癌症中的MSI和TMB有关，最常见的基因组突变类型是“突变”。“在蛋白质-蛋白质相互作用(PPI)网络中，我们发现了I型干扰素,吞噬作用,泛素酶，肿瘤通路显著丰富。最后,根据DDX58的表达表明潜在的敏感药物，如西迪拉尼布，VE-821,伊曲康唑,JNJ-42756493、IWR-1和Linsitinib。
未经批准：总而言之，我们获得了DDX58如何促进肿瘤发展的新见解，和DDX58可用作免疫相关的生物标志物，并作为COVID-19感染癌症患者的潜在免疫治疗靶点。
